Table 2.
Demographics, baseline characteristic and prior treatment of 15 patients administrated with Peg-rhArg1
| No. of Patients | Percentage (%) | |
|---|---|---|
| Characteristics | ||
| Sex | ||
| Male | 12 | 80 |
| Female | 3 | 20 |
| Age (years) | ||
| Median | 57 | |
| Range | 33–74 | |
| Karnofsky Performance Scale | ||
| 100 | 6 | 40 |
| 90 | 7 | 46.7 |
| 80 | 2 | 13.3 |
| Hepatitis Serology | ||
| Hep Bs Ag positive | 13 | 86.7 |
| Child-Pugh Status | ||
| A | 11 | 73.3 |
| B | 4 | 26.7 |
| Alpha-fetal Protein (AFP) | ||
| <=400 | 5 | 33.3 |
| >400 | 10 | 66.7 |
| Disease stage at the time of study entry | ||
| AJCC Staging | ||
| IIIA | 4 | 26.7 |
| IIIC | 3 | 20 |
| IV | 8 | 53.3 |
| BCLC Staging | ||
| C | 15 | 100 |
| Distant Metastases | ||
| Lung | 6 | 40 |
| Bone | 1 | 6.7 |
| Adrenal | 2 | 13.3 |
| Brain | 1 | 6.7 |
| Invasion of Major Vessels | ||
| Portal vein invasion | 5 | 33.3 |
| Prior Treatment | ||
| Surgical treatment | ||
| Liver resection | 5 | 33.3 |
| Laparotomy | 1 | 6.7 |
| Local ablative procedures | ||
| TACE | 6 | 40 |
| RFA | 1 | 6.7 |
| Systemic therapy | 7 | 46.7 |
AJCC American Joint Committee on Cancer staging; BCLC Barcelona Clinic Liver Cancer staging; Hep Bs Ag Hepatitis B surface antigen; TACE Transarterial chemo-embolization; RFA Radiofrequency ablation